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Introduction: The FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis plays a fundamental role in proliferation
and differentiation of dendritic cells (DCs). As DCs play an important role in rheumatoid arthritis (RA) immunopathology
we studied in detail the Flt3L/CD135 axis in RA patients.
Methods: The levels of Flt3L in (paired) serum and synovial fluid (SF) were quantified by enzyme-link immunosorbent
assay (ELISA). Expression of Flt3L and CD135 in paired peripheral blood mononuclear cells (PBMCs) and synovial
fluid mononuclear cells (SFMCs) was quantified by fluorescence-activated cell sorting (FACS). The expression of
Flt3L, CD135 and TNF-Converting Enzyme (TACE) in synovial tissues (STs) and in vitro polarized macrophages
and monocyte-derived DCs (Mo-DCs) was assessed by quantitative PCR (qPCR). CD135 ST expression was
evaluated by immunohistochemistry and TACE ST expression was assessed by immunofluorescence. Flt3L serum
levels were assessed in RA patients treated with oral prednisolone or adalimumab.
Results: Flt3L levels in RA serum, SF and ST were significantly elevated compared to gout patients and healthy
individuals (HI). RA SF monocytes, natural killer cells and DCs expressed high levels of Flt3L and CD135
compared to HI. RA ST CD68+ and CD163+ macrophages, CD55+ fibroblast-like synoviocytes (FLS), CD31+
endothelial cells or infiltrating monocytes and CD19+ B cells co-expressed TACE. IFN-γ-differentiated
macrophages expressed higher levels of Flt3L compared to other polarized macrophages. Importantly, Flt3L
serum levels were reduced by effective therapy.
Conclusions: The Flt3L/CD135 axis is active in RA patients and is responsive to both prednisolone and
adalimumab treatment. Conceivably, this ligand receptor pair represents a novel therapeutic target.Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory,
autoimmune disease characterized by persistent synovitis
and hyperplasia of the joint synovium, development of
pannus, and invasion of leukocytes into the joint
followed by destruction of local articular components
such as cartilage and bone [1,2]. In the RA synovium a
variety of cell types can be found, specifically T cells, B
cells, macrophages and dendritic cells (DCs) [3,4]. DCs
derive from two sources: stem cells in the bone marrow,* Correspondence: lebre@amc.uva.nl
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reproduction in any medium, provided the orand precursor cells found in the circulation. In humans there
are four major groups of DCs so far characterized: myeloid
DCs (mDCs), plasmacytoid DCs (pDCs), migratory DCs
such as Langerhans cells and dermal DCs, and monocyte-
derived DCs (mo-DC) [5]. Although DCs represent a
relatively small subset of immune cells, they are widely dis-
tributed throughout lymphoid and nonlymphoid tissues [6].
DCs have a crucial role in the initiation of primary im-
mune responses. Individuals with autoimmune disease
show a high number of aberrantly activated DCs either
in circulation or in the autoimmune lesions, secreting large
amounts of proinflammatory cytokines that mediate in-
flammation and differentiation of pathogenic T-helper type
1 and T-helper type 17 cells [7]. Rheumatoid synovial DCs
have been described as having a more mature, differentiated
phenotype, expressing high levels of HLA-DR, CD86 and
nuclear RelB, and have been observed to associate with TLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing the postcapillary venules, and in germinal center-like
structures [8]. In addition, the RA synovium contains abun-
dant immature mDCs and pDCs that express cytokines
(interleukin (IL)-12, IL-15, IL-18, and IL-23), HLA class II
molecules, and costimulatory molecules that are necessary
for T-cell activation and antigen presentation [9]. In the
synovial fluid (SF), DCs exhibit a semi-mature phenotype
showing low levels of CD80 and CD83 expression [9]. An
important sequel of continued antigenic stimulation via
DCs is the formation of lymphoid structures at the site of
inflammation. By coordinating the recruitment and/or acti-
vation of other immune cells, DCs can drive the generation
of ectopic lymphoid tissues, as in the case of inflamed syno-
via in RA and systemic lupus erythematosus [10].
FMS-related tyrosine kinase 3 ligand (Flt3L) is crucial
for steady-state pDC and mDC development. Mice lack-
ing Flt3L have reduced numbers of DCs [11], as do mice
that are deficient in signal transducer and activator of
transcription 3 [12], which is an important molecule in
the Flt3L signaling cascade. Conversely, administration
of Flt3L to mice or humans leads to a dramatic increase
in DC numbers both in lymphoid and nonlymphoid or-
gans [13]. Flt3L is abundantly expressed in most human
tissues, as a membrane-bound form and/or as a secreted
form. Flt3L is initially synthesized as a membrane-bound
protein, which must be cleaved to become a soluble
growth factor. The extracellular domain alone has been
shown to be sufficient for bioactivity [14]. Ectodomain
shedding of Flt3L is metalloproteinase dependent and is
mediated by tumor necrosis factor-converting enzyme
(TACE) [15], a type 1 membrane protein belonging to a
large family of transmembrane metalloproteases (a disin-
tegrin and metalloprotease domain gene family) that was
originally identified as the enzyme responsible for the
cleavage of pro-tumor necrosis factor (TNF) alpha [16],
but also has numerous additional substrates and func-
tions, including a critical role in activating the ligands of
the epidermal growth factor receptor, and in the modu-
lation of immune reactions [17]. The receptor for Flt3L,
CD135 is a transmembrane receptor tyrosine kinase
expressed in bone marrow cells during the early stages
of hematopoiesis [18], where it is involved in the control
of maintenance, expansion, mobilization and differenti-
ation of progenitor cells [19]. CD135 is required for DC
homeostasis, and inhibition of CD135-mediated signals
results in fewer DCs [20]. The effects of CD135
deficiency are most evident in the periphery, where this
receptor is essential for the homeostatic expansion of
DC progenitor populations in lymphoid organs [21].
Flt3L has been shown to accumulate in RA SF and in-
duces arthritis when injected into healthy mouse knee
joints. In addition, administration of Flt3L worsens experi-
mental arthritis, while tyrosine kinase inhibitors that targetCD135 alleviate experimental arthritis in mice models
[22,23]. Given the relevance of Flt3L/CD135 in early
hematopoiesis and DC generation, and possible involve-
ment in RA, we characterized in detail the expression of
both receptor and ligand in RA patients in comparison with
healthy individuals (HI) and non-RA disease controls.
Methods
Patients and controls
Patients with RA diagnosed according to the 2010 criteria
defined by the European League Against Rheumatism [24]
were included in the study. Gout patients and HI were used
as controls.
Peripheral blood mononuclear cells (PBMC) and synovial
fluid mononuclear cells were isolated by gradient centrifu-
gation with Lymphoprep (Axis-Shield PoPAS, Dieren, the
Netherlands). Cells were frozen in fetal calf serum (Invitro-
gen, Breda, the Netherlands) containing 10% dimethyl
sulfoxide (Sigma Aldrich, Zwijndrecht, the Netherlands)
until further experimentation. SF samples were obtained by
arthrocentesis of inflamed knee joints. Cell-free SF samples
were stored at −80°C. Synovial tissue (ST) specimens were
obtained during arthroscopy (2.7 mm arthroscope; Storz,
Tuttlingen, Germany) under local anesthesia [25]. The sam-
ples were snap frozen en bloc in Tissue-Tek OCT (Miles
Diagnostics, Elkhart, IN, USA). The frozen blocks were
stored in liquid nitrogen. Cryostat sections (5 μm) were
mounted on glass slides (Star Frost adhesive slides;
Knittelgläser, Braunschweig, Germany). The glass slides
were sealed and stored at −80°C until immunohistological
analysis. Demographic and clinical data of the patients are
presented in Table 1. All patients gave written informed
consent before inclusion in the study, and the study was ap-
proved by the Local Ethics Committee of the Academic
Medical Center, University of Amsterdam.
Enzyme-linked immunosorbent assay
Serum and SF levels of Flt3L were determined by
enzyme-linked immunosorbent assay (R&D Systems,
Abingdon, UK) following the manufacturer’s instruc-
tions. Demographic and clinical data of the patients
used in each experiment are presented in Table 2. To
determine the relationship between serum Flt3L levels
and clinical response in RA patients, Flt3L serum
levels were also measured in patients who started
treatment with either a different regimen of glucocorti-
coids or adalimumab.
Patients treated with high-dose glucocorticoids
Nine patients from the active arm of a previously con-
ducted, double-blind, randomized, placebo-controlled
trial were treated with 60 mg oral prednisolone daily for
1 week followed by 40 mg prednisolone daily during the
second week [26]. Flt3L serum levels were measured at
Table 1 Demographic and clinical characteristics of






Age (years) 56 ± 13 74 ± 17
Sex, female/male 13/3 2/10
Disease duration (years) 10.3 ± 14.4 2.2 ± 3.5
Swollen joint count 7 ± 5 2 ± 3
C-reactive protein (mg/l) 26.6 ± 21.2 18.2 ± 17.75
Disease Activity Score in 28 joints 5.0 ± 1.2 nd
Erythrocyte sedimentation
rate (mm/hour)
40.2 ± 30.3 27.7 ± 19.2
IgM-RF (kU/l) 493 ± 1406 nd










Number taking anti-tumor necrosis
factor (positive/negative)
0/15 0/12
Data presented as mean ± standard deviation or number. anti-CCP, anti-cyclic
citrullinated protein; DMARD, disease-modifying anti-rheumatic drug; IgM-RF,
IgM rheumatoid factor; nd, not determined; NSAID, nonsteroidal
anti-inflammatory drug.
Table 2 Demographic and clinical characteristics of
rheumatoid arthritis paired serum and synovial fluid
(enzyme-linked immunosorbent assay)
Rheumatoid arthritis paired
samples (n = 9)
Age (years) 58 ± 14
Sex, female/male 5/2
Disease duration (years) 15 ± 6
Swollen joint count 4 ± 4
C-reactive protein (mg/l) 20 ± 25




IgM-RF (kU/l) 117.25 ± 273.1










Number taking anti-tumor necrosis
factor (positive/negative)
2/9
Data presented as mean ± standard deviation or number. anti-CCP, anti-cyclic
citrullinated protein; DMARD, disease-modifying anti-rheumatic drug; IgM-RF,
IgM rheumatoid factor; nd, not determined; NSAID, nonsteroidal
anti-inflammatory drug.
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defined as a decrease in Disease Activity Score in 28
joints ≥1.2 after 2 weeks of glucocorticoid (prednisolone)
treatment.
Patients treated with adalimumab
Baseline demographic and clinical features of patients
from the larger open-label, prospective, single-center
adalimumab clinical trial have been described previously
[27]. Forty-eight patients were included for the present
analysis. All patients received 40 mg adalimumab sub-
cutaneously every other week, in combination with a
stable methotrexate dose for at least 16 weeks. Use
of oral glucocorticoids (prednisone ≤10 mg/day) was
allowed. Clinical response at 16 weeks was determined
according to the European League Against Rheumatism
response criteria [24].
Flow cytometry
The expression of specific markers was investigated in
PBMC/synovial fluid mononuclear cells by fluorescence-
activated cell sorting analysis after surface or intracellu-
lar staining with specific antibodies that were conjugated
to different fluorescent dyes. For the extracellular staining,
cells were washed in phosphate-buffered saline containing1% bovine serum albumin and 0.02% sodium azide and
were incubated with specific antibodies for 30 minutes at
4°C. Intracellular staining for Flt3L was performed after
staining for surface markers was completed (T cell, B cell,
natural killer (NK) cell and DC markers) using paraformal-
dehyde 4% as a fixation method followed by saponin
permeabilization and Flt3L staining for 30 minutes at 4°C.
For further details see Additional file 1. Flow cytometry was
performed using a FACS CANTO (Becton Dickinson,
Breda, the Netherlands) and analyzed with Flowjo analysis
software (Tree Star, Ashland, OR, USA).
Immunohistochemistry
Briefly, endogenous peroxidase activity was inhibited
in the acetone-fixed sections by 0.1% sodium azide and
0.3% hydrogen peroxide in phosphate-buffered saline.
Sections were stained using mouse monoclonal anti-
bodies against CD68 (clone EBM-11; Dako, Heverlee,
the Netherlands), CD163 (clone 5cFAT; BMA Biomedi-
cals, Augst, Switzerland) or CD135 (clone BV10A4H2;
eBiosciences, Vienna, Austria). Sections were sequentially
incubated with a secondary horseradish peroxidase-
labeled antibody, followed by horseradish peroxidase de-
tection using the AEC kit (Brunschwig, Amsterdam, the
Netherlands), and hematoxylin (Klinipath, Duiven, the
Netherlands) as the counterstain. Parallel sections were
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matched monoclonal antibodies as negative controls.
After immunohistochemical staining, coded sections
stained for CD135, CD68 or CD163 were analyzed in a
random order by computer-assisted image analysis
[28]. For all markers, 18 high-power fields were ana-
lyzed. Images were analyzed with the Qwin analysis
system (Leica, Cambridge, UK).Table 3 Demographic and clinical characteristics of
rheumatoid arthritis and gout synovial tissue





Age (years) 60 ± 8 62 ± 14
Sex, female/male 13/9 2/10Immunofluorescence
Frozen ST sections were fixed in acetone and blocked
with 10% human serum (Dako, Glostrup, Denmark),
followed by incubation with mouse purified monoclonal
antibody against TACE (R&D Systems ) for 1 hour. After
washing with phosphate-buffered saline/bovine serum albu-
min 1%, sections were incubated with a secondary horse-
radish peroxidase-labeled antibody for 30 minutes. For
detection of the first primary antibody, a biotin-conjugated
tyramide signal amplification (PerkinElmer Life Sciences,
Boston, MA, USA) was used followed by streptavidin
Alexa 594 antibody (Invitrogen, Bleiswijk, the Netherlands).
After blocking with 10% mouse serum (Dako), the sections
were incubated with fluorescein isothiocyanate-labeled
mouse monoclonal antibodies against CD68 (BioLegend,
London, UK), CD163 (BioLegend), CD19 (eBiosciences),
CD55 (Becton Dickinson), CD3 (eBiosciences), CD31
(eBiosciences), or purified rabbit polyclonal von Willebrand
factor (Dako) followed by a secondary antibody labeled with
Alexa 488. The slides were mounted with Vectashield
containing diamidino-2-phenylindole (Vector Laboratories,
Burlingame, CA, USA) and were analyzed on a fluorescent
imaging microscope (Leica DMRA, Wetzlar, Germany)
coupled to a charge-coupled device camera.Disease duration (years) 13 ± 14 2.3 ± 1.7
Swollen joint count 7 ± 5 2 ± 3
C-reactive protein (mg/l) 20 ± 26 36 ± 31
Disease Activity Score in 28 joints 5.0 ± 1.2 nd
Erythrocyte sedimentation rate
(mm/hour)
38 ± 31 35 ± 20
IgM-RF (kU/l) 464 ± 1366 nd










Number taking anti-tumor necrosis
factor (positive/negative)
6/22 0/12
Data presented as mean ± standard deviation or number. anti-CCP, anti-cyclic
citrullinated protein; DMARD, disease-modifying anti-rheumatic drug; IgM-RF,
IgM rheumatoid factor; nd, not determined; NSAID, nonsteroidal
anti-inflammatory drug.Monocyte purification, macrophage and dendritic cell
differentiation
PBMCs were isolated from volunteer donor blood buffy
coats (Sanquin, Amsterdam, the Netherlands) by gradient
centrifugation with Lymphoprep (Axis-Shield PoPAS), and
monocytes were further isolated by Percoll gradient
separation (GE Healthcare, Zeist, the Netherlands). Differ-
entiation of monocytes into macrophages was performed
in IMDM/10% fetal calf serum supplemented with
100 μg/ml gentamycin (Invitrogen), in the presence of
granulocyte–macrophage colony-stimulating factor (5 ng/
ml), macrophage colony-stimulating factor (25 ng/ml),
interferon-gamma (IFNγ, 10 ng/ml) or IL-10 (10 ng/ml) (all
from R&D Systems) for 7 days. mo-DCs were differentiated
in IMDM/5% fetal calf serum supplemented with 100 μg/
ml gentamycin (Invitrogen), in the presence of granulo-
cyte–macrophage colony-stimulating factor (50 ng/ml) and
IL-4 (100 ng/ml) for 6 days.Quantitative measurement of mRNA expression
Gene expression (mRNA) in synovial biopsies from RA
and gout patients, polarized macrophages and mo-DC
was assessed by quantitative polymerase chain reaction
(qPCR) as described in detail in Table 3. Demographic
and clinical data of the patients used in each experiment
are presented in Table 3.
Statistical evaluation
All analyses were performed using Prism software (Graph-
Pad, La Jolla, CA, USA). Flt3L levels in paired serum and
SF from RA patients and controls were compared using the
Wilcoxon matched-pairs test and the Mann–Whitney
U test, respectively. Results from qPCR and immunohisto-
chemistry were analyzed using the Mann–Whitney U test.
Results from fluorescence-activated cell sorting analysis and
qPCR for polarized macrophages and mo-DCs were ana-
lyzed using the Kruskal–Wallis test. P <0.05 was considered
statistically significant.
Results
Flt3L levels in RA serum, synovial fluid and synovial tissue
are significantly elevated
We found significantly higher levels of Flt3L in serum of
RA patients compared with HI (Figure 1A, P = 0.0027).
Figure 1 FMS-related tyrosine kinase 3 ligand levels in rheumatoid arthritis serum, synovial fluid and synovial tissue are significantly
elevated. (A) FMS-related tyrosine kinase 3 ligand (Flt3L) serum levels (S) were increased in rheumatoid arthritis (RA; n = 9) compared with
healthy individuals (HI; n = 19) (P = 0.0027). (B) Flt3L serum levels were elevated in RA synovial fluid (SF) compared with paired serum (n = 9)
(P = 0.0019 (C). Gene expression analysis by quantitative polymerase chain reaction showed increased Flt3L expression in RA synovial tissue (ST; n= 22)
compared with gout ST (n= 12) (P= 0.0450). Each data point represents a single subject. Results presented as mean ± standard error of the mean mRNA
expression of Flt3L relative to GAPDH. *P <0.05, **P <0.01.
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(P = 0.0019) in the Flt3L levels in SF of RA patients
compared with paired serum (Figure 1B). Consistent
with increased activation of the Flt3L/CD135 axis in the
synovial compartment of RA patients, we found in-
creased mRNA levels of Flt3L in RA ST compared with
gout ST (Figure 1C, P = 0.045). These differences could
not be attributed to inflammation status since RA and
gout patients were matched for IL-6 and IL-8 inflamma-
tory parameters (Figure S1C,D in Additional file 2).
Rheumatoid arthritis synovial fluid monocytes, natural
killer cells and dendritic cells express high levels of Flt3L
To investigate the sources of Flt3L in peripheral blood (PB)
and SF we characterized the relative expression of Flt3L on
CD14+ monocytes, CD19+ B cells, CD56+ NK cells, CD4+
and CD8+ T cells and both CD1c+ mDCs and CD304+
pDCs present in RA paired synovial fluid mononuclear cells
and PBMC and in HI PBMC by flow cytometry. During
normal hematopoiesis, Flt3L is expressed constitutively but
most of it is retained intracellularly within the Golgi appar-
atus [29]. We characterized in detail both intracellular and
extracellular expression of Flt3L. We observed that the per-
centage of extracellular Flt3L on CD14+ monocytes was sig-
nificantly higher (Figure 2A, P = 0.0083) in RA SF compared
with PB. In addition, the percentage of PB RA CD14+
monocytes that expressed extracellular Flt3L was signifi-
cantly higher (Figure 2A, P= 0.04) compared with HI PB.
The mean fluorescence intensity (MFI) is a measure-
ment of expression per cell basis. In this respect, no dif-
ferences were observed in extracellular Flt3L (expressed
as MFI) on CD14+ monocytes from RA PB compared
with paired SF (Figure 2A). We observed an increase in
the percentage of intracellular Flt3L by CD14+ mono-
cytes in RA SF compared with RA PB. Moreover, SF
monocytes had a higher capacity to express Flt3L (MFI)compared with RA PB (Figure 2A, P= 0.0318 and
P= 0.0291 respectively). The percentage of CD56+ NK cells
that expressed Flt3L extracellularly or intracellularly was
similar in HI and RA patients (Figure 1B). The expression
of extracellular Flt3L (per cell basis, MFI) by CD56+ NK
cells in RA SF was significantly higher (Figure 1B,
P= 0.0191) compared with paired PB. In addition, in CD56+
NK cells RA PB expressed significantly higher levels of
extracellular Flt3L compared with HI PBMC (Figure 1B,
P= 0.0007). CD1c+ mDCs in RA SF expressed higher extra-
cellular Flt3L compared with paired RA PB (Figure 2C,
P= 0.0317). No differences were observed in the percentage
of CD1c+ mDC-expressing Flt3L intracellularly or extracel-
lularly in RA patients compared with HI, and no differences
were observed in the levels expressed on a per cell basis. In
RA SF, CD304+ pDCs expressed significantly higher
(Figure 2D, P = 0.0015) levels of extracellular Flt3L com-
pared with paired PB. No differences were observed on a
per cell basis for intracellular Flt3L expression.
T cells contain intracellularly stored Flt3L but express
low levels of extracellular Flt3L at the cell surface, as shown
by flow cytometry analysis (Figure S1A,B in Additional file
2; see also [30]). Here we did not observe statistically sig-
nificant differences in the percentage or level expressed on
a per cell basis of Flt3L by both CD4+ and CD8+ T cells in
PB and (paired) SF (Figure S2A,B in Additional file 3). The
expression of Flt3L by CD19+ B cells was not significantly
different between HI and RA PB or between paired RA PB
and SF (Figure S2C in Additional file 3).
CD135 is expressed in RA, gout and healthy individual
synovial tissue
Representative photomicrographs of CD135 expression
(reddish-brown staining) in RA, gout and HI STs are
shown in Figure 3A. The expression of Flt3L receptor
CD135 in STs was similar between RA, gout and HI as
IntracelullarExtracelullar





















































































































































































































































Figure 2 Characterization of FMS-related tyrosine kinase 3 ligand expression in rheumatoid arthritis paired peripheral blood mononuclear
cells (PBMC) and synovial fluid mononuclear cells and in healthy individual PBMC. Intracellular and extracellular expression of FMS-related tyrosine
kinase 3 ligand (Flt3L) by all cell types shown in terms of percentage or mean fluorescence intensity (MFI) (cellular marker+Flt3L+). (A) Percentage of
extracellular Flt3L by CD14+ monocytes was significantly higher in rheumatoid arthritis (RA) peripheral blood (PB) compared with healthy individuals (HI;
n= 10 and n= 5 respectively, P= 0.0400) and in RA synovial fluid (SF) compared with paired PB (n= 10, P= 0.0083). The percentage of intracellular Flt3L by
CD14+ monocytes was increased in RA SF compared with paired PB. SF monocytes express higher Flt3L (MFI) compared with RA PB (P= 0.0318 and P=
0.0291 respectively). (B) Expression of extracellular Flt3L (MFI) by CD56+ natural killer (NK) cells in RA SF was significantly higher (P= 0.0191) compared with
paired PB. CD56+ NK cells in RA PB expressed significant higher levels of extracellular Flt3L compared with HI peripheral blood mononuclear cells (PBMC;
P= 0.0007). (C) CD1c+ myeloid dendritic cells (mDC) in RA SF expressed higher extracellular Flt3L compared with paired RA PB (P= 0.0317). (D) CD304+
plasmacytoid DC in RA SF expressed significant higher (P= 0.0015) levels of extracellular Flt3L compared with paired PB. Bars represent mean (± standard
error of the mean) of five to 10 RA patients and HI. *P <0.05, **P <0.01.
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addition, we also measured mRNA expression of
CD135 in RA and gout ST and there was no difference
in expression between the two diseases, which con-
firmed the protein data obtained by immunohisto-
chemistry (Figure 3B, right panel). We also performed
immunohistochemistry to detect CD68+ and CD163+
macrophages to assess the level of synovial inflamma-
tion and measured IL-6 and IL-8 levels by qPCR. We
observed that RA and gout patients were matched
for these inflammatory parameters (Figure S1C,D in
Additional file 2).Rheumatoid arthritis synovial fluid monocytes,
NK cells and plasmacytoid DC express high levels of
CD135
The percentage of CD14+ monocytes expressing
CD135 was significantly (Figure 3C, P = 0.0115) higher
in RA PB compared with HI PB. In addition, the ex-
pression of CD135 by CD14+ monocytes was signifi-
cantly higher in RA SF compared with paired PB both
expressed as a percentage of positive cells (Figure 3C,
P = 0.0115) or as MFI (P = 0.0260). In RA PB, CD56+
NK cells showed significantly (Figure 3C, P = 0.0115)
elevated expression (based only on MFI) of CD135
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percentage of positive cells or MFI of CD1c+ mDC ex-
pressing CD135 in RA compared with HI, nor in RA
PB compared with paired SF. The percentage of
CD304+ pDC expressing CD135 was significantly
higher in RA SF compared with paired PB (Figure 3C,
P = 0.0029) while no differences were observed in
terms of MFI. We observed that both the percentageFigure 3 CD135 expression in healthy individuals and rheumatoid a
observed in CD135 expression in rheumatoid arthritis (RA) patient (n = 1
tissues (STs) by immunohistochemical analysis. (B) Right: CD135 gene ex
quantitative polymerase chain reaction. Results presented as mean ± sta
to GAPDH. No differences were observed. (C) CD135 expression on CD1
dendritic cells (DC), CD19+ B cells and CD1c+ myeloid DC by flow cytom
CD135+CD14+ monocytes was higher in RA peripheral blood (PB) comp
CD135+CD56+ NK cell MFI was higher compared with HI PB (P = 0.0115).
myeloid DC in RA compared with HI, or RA PB compared with paired syn
was higher in RA SF compared with paired PB (P = 0.0029). Both the perc
compared with paired PB (P = 0.0068 and P = 0.0491 respectively). Graph
**P <0.01.and expression per cell basis (MFI) of CD135 by CD4+
or CD8+ T cells did not differ between RA and HI PB
nor between RA SF and paired PB (data not shown). In
contrast with the results obtained for Flt3L, the ex-
pression of CD135 by CD19+ B cells was significantly
higher in RA SF compared with paired PB, both in
terms of percentage of positive cells (Figure 3C, P =
0.0068) and MFI (Figure 3C, P = 0.0491).rthritis and gout patients. (A), (B) No differences were
2), gout patient (n = 11) and healthy individual (HI; n = 7) synovial
pression in STs of RA (n = 22) and gout (n = 12) patients by
ndard error of the mean (SEM) mRNA expression of CD135 relative
4+ monocytes, CD56+ natural killer (NK) cells, CD304+ plasmacytoid
etry. The percentage and mean fluorescence intensity (MFI) of
ared with HI PB (P = 0.0115 and P = 0.0260 respectively). In RA PB,
There were no differences for percentage or MFI of CD135+CD1c+
ovial fluid (SF). The CD135+CD304+ plasmacytoid DC percentage
entage and MFI of CD135+CD19+ B cells were higher in RA SF
s represent mean ± SEM of five to 10 RA patients and HI. *P <0.05,
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synoviocytes, CD31+ endothelial cells and CD19+ B cells
express TACE in RA synovial tissue
Flt3L can be proteolytically cleaved from the cell mem-
brane by TACE [15]. In order to investigate the cellular
source(s) of TACE in RA ST, immunofluorescence
analysis was performed. TACE was expressed by several
cell types in the RA synovium (Figure 4A; and Figure
S3A in Additional file 4). These included CD68+ intimal
macrophages, CD55+ fibroblast-like synoviocytes, CD31+
endothelial cells or infiltrating monocytes and CD19+ B
cells (Figure 4A). CD3+ T cells and vWF+ blood vessels
did not express TACE (Figure S3B in Additional file 4).
In addition, TACE expression levels (mRNA) in RA and
gout ST were similar (Figure 4B).
IFNγ-differentiated macrophages express high levels
of Flt3L
The local environment plays a critical role in shaping or
directing the pattern or pathway of macrophage and DC



















Figure 4 Double immunofluorescence staining of TACE+ cells in rheu
other cellular markers (green) can be seen. Tumor necrosis factor-convertin
CD163+ macrophages, CD55+ fibroblast-like synoviocytes, CD19+ B cells an
arthritis (RA) patients. (B) Gene expression analysis of TACE mRNA by quan
(n = 12) synovial tissue analyzed by qPCR. Results presented as mean ± stan
No significant differences were observed.Flt3L, CD135 and TACE expression with differentiation,
we differentiated monocytes into macrophages using
several polarizing conditions or into mo-DC and evalu-
ated the expression of these markers. We observed
that IFNγ-differentiated macrophages expressed higher
levels of Flt3L compared with all the other polarizing
conditions (Figure 5A; IFNγ vs. monocytes, P = 0.0317;
IFNγ vs. IL-10, P = 0.0079; IFNγ vs. macrophage colony-
stimulating factor and granulocyte–macrophage colony-
stimulating factor, P = 0.0043). There was a trend towards
higher Flt3L expression in mo-DC compared with mono-
cytes but these differences did not reach statistical signifi-
cance (Figure 5A). The expression level of CD135 tends to
decrease with increasing differentiation [31]. Indeed, we ob-
served that CD135 expression is highest in monocytes and
downregulated upon differentiation into macrophages
(Figure 5B). There was a trend towards lower CD135 ex-
pression levels in mo-DC compared with monocytes but
these differences were not statistically significant (Figure 5B).
TACE expression was similar in monocytes and polarized
macrophages and in monocytes and mo-DC (Figure 5C).Mouse IgG1
TACE/CD19
matoid arthritis synovial tissue. (A) TACE+ single cells (red) and
g enzyme (TACE) was colocalized (yellow, arrows) with CD68+ and
d CD31+ endothelial cells. Figures are representative of five rheumatoid
titative polymerase chain reaction (qPCR) in RA (n = 22) and gout
dard error of the mean mRNA expression of TACE relative to GAPDH.
Figure 5 Gene expression of FMS-related tyrosine kinase 3 ligand, CD135 and tumor necrosis factor-converting enzyme by in vitro
polarized human macrophages and monocyte-derived dendritic cells. Macrophages and monocyte-derived dendritic cells (mo-DCs)
differentiated as stated in Methods. (A) Interferon-gamma (IFNγ)-differentiated macrophages expressed higher levels of FMS-related tyrosine
kinase 3 ligand (Flt3L) compared with all the other polarizing conditions (IFNγ vs. monocytes, P = 0.0317; IFNγ vs. interleukin (IL)-10, P = 0.0079; IFNγ vs.
macrophage colony-stimulating factor (M-CSF) and granulocyte–macrophage colony-stimulating factor (GM-CSF), P = 0.0043). There was a trend for
higher Flt3L expression in mo-DC compared with monocytes but these differences did not reach statistical significance. (B) CD135 expression is higher
in monocytes and is downregulated upon differentiation into macrophages. There was a trend for lower of CD135 expression in mo-DC compared
with monocytes but these differences were not statistically significant. (C) Tumor necrosis factor-converting enzyme (TACE) expression was similar in
monocytes and polarized macrophages and in monocytes and mo-DC. Bars represent mean ± standard error of the mean of at least five independent
donors’ mRNA expression of each gene relative to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). *P <0.05, **P <0.01, ***P <0.001. monos.
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effective treatment
Having shown increased levels of Flt3L in RA patients,
we next asked the question of whether effective treat-
ment could reduce Flt3L concentrations, which would
suggest an effect on DCs associated with clinical im-
provement. Figure 6A shows significantly decreasedFlt3L levels after prednisolone treatment (P = 0.02). There
was a significant correlation between the Disease Activity
Score in 28 joints and Flt3L serum levels (baseline and
post treatment) (Figure 6B; r = 0.63, P = 0.0078). Similarly,
there was a nonsignificant trend towards lower serum

















































































Figure 6 FMS-related tyrosine kinase 3 ligand serum levels in response to prednisolone or adalimumab therapy in rheumatoid arthritis
patients. Serum was collected at baseline and post treatment, at 2 weeks in case of prednisolone treatment and 16 weeks for adalimumab
treatment. Adalimumab patients were further discriminated between responders, moderate responders and nonresponders based on European
League Against Rheumatism criteria. FMS-related tyrosine kinase 3 ligand (Flt3L) serum levels were assessed by enzyme-linked immunosorbent
assay before and after therapy. (A) Serum levels of Flt3L decreased significantly (P = 0.02) after prednisolone treatment. (B) Positive correlation
between the Disease Activity Score in 28 joints (DAS28) and Flt3L serum levels in prednisolone-treated patients (P = 0.0078, r = 0.63). (C) A trend
towards lower serum levels of Flt3L was observed in RA patients (only responders) after adalimumab treatment. *P < 0.05.
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In the present study we show in RA patients the expres-
sion of Flt3L and its receptor in three different compart-
ments: blood, SF and ST. Flt3L was significantly elevated
in RA SF compared with paired serum, confirming pre-
vious observations [23]. In addition, we reported for the
first time that RA serum contains significantly elevated
levels of Flt3L compared with HI serum. Moreover, we
observed a higher expression of Flt3L (mRNA) in STs of
RA patients compared with gout patients. RA and gout
samples were matched in terms of macrophage numbers
and IL-6 and IL-8 expression. This might indicate that
Flt3L levels might reflect disease specificity more than
just inflammation.
A detailed analysis of cellular components in paired
blood and SF revealed that monocytes are the major cell
population that expresses extracellular Flt3L. Monocytes
are bone marrow-derived cells that mediate essential
regulatory and effector functions in innate and adaptive
immunity [32]. Circulating PB monocytes migrate into
tissues, where they differentiate into different effectorcells such as macrophages, DC and osteoclasts [33] that
are of importance in RA pathology. The percentage of
circulating CD14+ Flt3L+ monocytes is increased in RA
patients, compared with HI. Moreover, in RA SF the
percentage of Flt3L-expressing monocytes is significantly
higher compared with paired PB. Importantly, RA SF
monocytes have a superior capacity to express Flt3L
on a per cell basis compared with PB (circulating)
monocytes. Mobilization of preformed Flt3L from intra-
cellular stores rather than de novo synthesis might be
responsible for increased Flt3L levels at the site of
inflammation. Flt3L is a crucial growth factor for DC
differentiation that leads to increased numbers of these
cells both in mice and humans [13]. Interestingly, Flt3L
can substitute for macrophage colony-stimulating factor
in support of osteoclast differentiation and function [34],
raising the possibility of a direct role for Flt3L in bone
damage in RA.
The expression of the receptor for Flt3L, CD135, is
elevated in RA PB monocytes compared with HI PB
monocytes. In addition, we show that RA SF monocytes
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monocytes. Coexpression of CD135 and its ligand in the
same cell (in this case by RA monocytes) suggests a
possible autocrine stimulatory mechanism, as already
reported for primary acute myeloid leukemia (AML) [35].
TACE is the major sheddase for Flt3L [15]. Flt3L is
primarily produced as a membrane-bound protein [36]
and soluble Flt3L is generated through ectodomain
shedding [15]. TACE has been implicated in RA due to
its role in processing membrane-bound TNF to its sol-
uble form [37]. Previous studies have demonstrated a
central role for TNF in RA, and early preclinical studies
indicated that inhibition of TACE was beneficial for pa-
tients with arthritis [38]. We observed that in RA ST the
main sources of TACE were macrophages (both CD68+
and CD163+ populations), CD55+ fibroblast-like syno-
viocytes, activated endothelial cells or infiltrating mono-
cytes (CD31+) and B cells (CD19+). As soluble Flt3L
levels are highly dependent on TACE activity, the above-
mentioned cells might contribute to local levels of sol-
uble Flt3L. Since the TACE expression level (mRNA) in
RA and gout STs was the same and Flt3L levels were in-
creased in RA ST, it is tempting to speculate that TACE
biological activity in RA might be elevated compared
with gout patients. This observation cannot be attributed
to a differential degree of ST inflammation between RA
and gout STs since the expression of the inflammatory
cytokines IL-6 and IL-8 and macrophages numbers
(CD68+ and CD163+ cells) was similar. Macrophages are
critically involved in the pathogenesis of RA [39]. Not
only do they produce a variety of proinflammatory cyto-
kines and chemokines, but macrophages also contribute
to cartilage and bone destruction [40]. In addition, it has
been reported that the number of macrophages in RA
ST correlates with bone damage and that increased
numbers of macrophages are an early hallmark of active
disease [3]. One of the main features of macrophages is
their high plasticity during development. The nomencla-
ture of general macrophage polarization has been pro-
posed in the last decade, in which M1 (classical,
inflammatory) and M2 (alternative, anti-inflammatory)
refer to the two extremes of a spectrum of possible
macrophage activation status [41]. M1 macrophages are
mainly present in RA and are characterized by a proin-
flammatory phenotype, producing high levels of TNF,
IL-1, IL-6, IL-12, reactive oxygen species, and low levels
of IL-10 [42]. Here we show for the first time that, in
addition to the above-mentioned inflammatory media-
tors, Flt3L might be considered a specific marker for
IFNγ-differentiated macrophages. Polarizing cytokines
such as IFNγ might contribute to the high levels of Flt3L
found in RA synovium by shifting the macrophage
polarization into a M1-like phenotype. Overall, these
data suggest that in RA, in addition to circulatingmonocytes, IFNγ-differentiated macrophages might be
an important source of Flt3L.
Sublining macrophages are a reliable biomarker for re-
sponse to therapy in RA [43]. We have previously shown
that oral prednisolone, an effective therapy in RA, was
associated with a reduction in macrophage infiltration in
ST [26]. In this study we observed a marked reduction
of Flt3L serum levels in RA patients after prednisolone
treatment, and a significant correlation between the
Disease Activity Score in 28 joints and Flt3L serum
levels. In addition, in the responder group of RA pa-
tients treated with adalimumab we observed a trend to-
ward reduced serum levels of Flt3L. The reduction of
Flt3L serum levels observed after effective treatment
might reflect the reduction in the numbers of the main
source(s) of Flt3L: circulating monocytes and/or ST
macrophages. Flt3L has recently been outlined within a
panel of preclinical biomarkers of predictive value for
the development of RA [44]. Flt3L levels might there-
fore be valuable as a potential biomarker of inflamma-
tion or response to treatment.
Conclusion
The Flt3L/CD135 axis is increased in RA patients
compared with HI and disease controls, and is respon-
sive to both prednisolone and adalimumab treatment.
Collectively these data suggest that the Flt3L/CD135 axis
might be important in RA pathophysiology.Additional files
Additional file 1: Contains a description of the methods from
Additional files 2, 3 and 4.
Additional file 2: Figure S1. Assessment of global ST inflammation.
(A-B) IL-6 and IL-8 gene expression level in STs from RA (n=22) and gout
(n=12) patients. Gene expression analysis by qPCR showed that IL-6 and
IL-8 expression was similar between RA ST compared to gout ST. Each data
point represents a single subject. Results are presented as mean±SEM
mRNA expression of IL-6 or IL-8 relative to GAPDH. *p < 0.05, **p < 0.01.
(C-D) Immunohistochemical analysis of CD68 and CD163 macrophage
markers in RA (n=12), gout (n=11) and HI (n=7) STs. CD68 and CD163
macrophage numbers were increased in RA and gout STs compared to
HI STs. No differences were observed between RA and gout STs.
Additional file 3: Figure S2. Characterization of Flt3L expression in RA
paired PBMC and SFMC and in HI PBMC. Intra- and extra-cellular
expression of Flt3L by all cell types is shown in terms of percentage or
MFI (cellular marker+ Flt3L+). No differences were observed for the
percentage or MFI of extracellular or intracellular Flt3L by CD4+ T cells
(A), CD8+ T cells (B) or CD19+ B cells (C) in RA compared to HI. Bars
represent the mean (±SEM) of 5-10 RA patients and HI. *p < 0.05,
**p < 0.01.
Additional file 4: Figure S3. Immunofluorescence staining of TACE+
cells in RA ST. (A) Single stainings for TACE+ (red) and other cellular
markers (green) can be seen. (B) Double immunofluorescence staining of
TACE+ cells in RA ST with CD3+ T cells and vWF+ blood vessels. TACE did
not colocalized with CD3+ T cells or with vWF+ blood vessels. Single
immunofluorescence stainings for TACE and vWF are also shown. Figures
are representative of five RA patients. Original magnification 250x.
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